Investor Presentation

IS/ISO9001:2015 IS/ISO14001:2015 Excel Industries Ltd. IS/ISO 45001:2018 Certifiedby BIS. 17th August, 2026 Certifiedby BIS. BSE Ltd. National Stock Exchange of India Ltd. Listing Department, Listing Department, Pheeroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Bandra (E), Mumbai-400 001 Mumbai-400 051 Sub: Investor Presentation Ref: BSE Scrip Code: 500650; NSE Scrip Code: EXCELINDUS Dear Sir/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Unaudited Financial Results for the quarter ended June 30, 2026. The Investor Presentation will also be available on the website of the Company i.e. www.excelind.co.in We request you to take the above information on record. Thanking you, Yours faithfully, For Excel Industries Limited S K Singhvi Company Secretary Encl: As above Chemicals Business / Environment & Biotech Division Excel Industries Limited Polymer Inputs / Pharmaceuticals Intermediaries/Veterinary API’s 184-87, S. V. Road, Jogeshwari (West), T: 91-22-66464200 Mumbai-400102, Maharashtra, India. W: http://www.excelind.co.in CIN: L24200MH1960PLC011807 EXCEL INDUSTRIES LIMITED Investor Presentation | Q1 FY27 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Excel Industries Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Q1 FY27 Financial Performance Q1 FY27 Results Highlights (Standalone) ₹ 294 Crs ₹ 42 Crs ₹ 29 Crs Revenue EBITDA PAT ➢ Erratic monsoon conditions impacted demand for the Agrochemical Intermediates product group ➢ Despite the underperformance in Agrochemical Intermediates, Q1 FY27 revenue reached ~95% of Q1 FY26 revenue ➢ Strong performance from other product groups largely offset the decline in Agrochemical Intermediates ➢ Revenue traction was supported by previously announced contract manufacturing projects with superior margin profiles ➢ Prudent supply chain management ensured no stock out during disruption amidst global volatility in Raw material pricing and availability ➢ EBITDA remained stable at ₹42 crore in Q1 FY27, despite lower revenues versus Q1 FY26 ➢ PAT declined by ₹5 crore YoY, primarily due to lower non-operating income ➢ Maintained market share in key products while continuing to diversify its product portfolio Timely Project Completion Reinforces Execution Excellence Key Milestone Strategic Impact ➢ Dedicated manufacturing project successfully ➢ Demonstrates Excel’s project execution completed on 23rd July 2026 as per agreed capability through timely completion Long Term Value timelines ➢ Reinforces customer confidence Creation with ➢ Supports supplies under the 5-year long term supply agreement with a leading specialty ➢ Diversifies revenue streams through specialty Revenue Potential chemicals company chemical manufacturing Rs. 35-40 Cr p.a. ➢ Dedicated Facility established with a planned ➢ Creates platform for additional opportunities in (Excluding Cost of capex of Rs. 40 crores the contract manufacturing segment Raw Materials) ➢ Customer commitment is in the form of trade advance of Rs 25 Cr Commenting on this development, Mr. Ravi Ashwin Shroff – Managing Director said, “We are pleased to announce the successful completion of the project for production for supplies against the long-term supply agreement on 23rd July 2026. The project has been completed as per the timelines agreed with the customer. This achievement underscores our execution abilities and our commitment towards fulfilling the customer expectations. This achievement will further strengthen our position as a reliable contract manufacturing partner, whilst diversifying our revenue base. We are hopeful that this will set the base for more opportunities for the company in the contract manufacturing space. ” New Product launch Setting up a 1,265 MTPA specialty chemical facility at Lote to diversify Capex Details the product portfolio. Amount Investment of Rs 5 crores approx. Expected launch – February 2027 post Completion commissioning of the production capacity Market potential in a wide range of Scope geographies. Standalone performance in Q1 FY27 Revenue (₹ in Crs) EBITDA (₹ in Crs) PAT (₹ in Crs) 42 42 294 29 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Revenue Profile (₹ in Crs) EBITDA PAT Margin (%) Margin (%) 309 294 13.7% 14.4% 10.8% 9.9% 69 61 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Domestic Export Reduction in PAT due to reduction in other income Outlook – Q2 FY27 Business Outlook ➢ Near-term demand challenges in Agrochemical Intermediates are expected to persist ➢ Non-agrochemical product groups are expected to maintain growth momentum and support overall performance ➢ With the dedicated manufacturing setup now commissioned, we are targeting higher volumes under the long-term specialty chemical supply agreement (announced in November 2025) ➢ Raw material price volatility, supply availability, and shipping disruptions are expected to continue into Q2; we remains agile in managing these challenges ➢ Development initiatives in Biocides and Performance Solutions remain on track, with product launches targeted during FY27 Standalone Profit and loss Statement Particulars (Rs. Cr) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Q-o-Q FY26 Revenue from Operations 293.7 309.5 -5.1% 281.1 4.5% 1,094.2 Cost of Goods Sold 146.8 168.5 161.0 6 [Showing first 8,000 characters — download PDF for full document]